Welcome to our dedicated page for Teva Pharm news (Ticker: TEVA), a resource for investors and traders seeking the latest updates and insights on Teva Pharm stock.
News about Teva Pharmaceutical Industries Limited (TEVA) focuses on its transformation into an innovative biopharmaceutical company, its generics and biosimilars franchise, and developments across neuroscience and immunology. Company announcements highlight progress on its Pivot to Growth strategy, including updates on branded medicines such as AUSTEDO, AJOVY and UZEDY, as well as late-stage pipeline assets.
Recent news includes clinical and regulatory milestones for AJOVY (fremanezumab-vfrm), where Phase 3 SPACE trial results in children and adolescents with episodic migraine were published in the New England Journal of Medicine. These data supported U.S. FDA approval for preventive treatment of episodic migraine in pediatric patients who meet specified criteria, adding to AJOVY’s existing indication in adults. News items provide details on trial design, efficacy outcomes, and safety profile.
Investors and followers of TEVA can also find updates on pipeline programs such as olanzapine extended-release injectable suspension (TEV-'749) for schizophrenia and the anti‑IL‑15 antibody TEV-'408 for vitiligo and celiac disease, including regulatory submissions and funding agreements. Teva’s news flow covers biosimilar approvals and collaborations, such as European Commission approvals for denosumab biosimilars PONLIMSI and DEGEVMA and the U.S. settlement and license agreement for AVT06, a proposed biosimilar to Eylea.
In addition, TEVA news features financial and capital markets events, including rating agency actions, amendments to credit facilities, quarterly earnings release dates, conference call schedules, and participation in major healthcare conferences. This mix of clinical, regulatory, strategic and financial updates makes the TEVA news page a central resource for tracking how Teva’s generics base, innovative pipeline and biosimilars portfolio contribute to its stated Pivot to Growth strategy. Users interested in TEVA stock can monitor this page for ongoing disclosures that may inform their understanding of the company’s operations and strategic direction.
Teva (NYSE: TEVA) published its 2025 Healthy Future Report highlighting sustainability and access-to-medicine achievements, including meeting all sustainability-linked bond targets totaling about $7.5 billion.
Key metrics: nearly 8 million people reached via product donations; 39% reduction in Scope 1–2 GHG since 2019; 32% reduction in Scope 3 since 2020; $36.4 billion in healthcare savings from generics across 21 countries; and >99% employee compliance training completion.
Teva (NYSE: TEVA) reported UZEDY U.S. net sales of $63 million in Q1 2026, up 62% year‑on‑year from $39 million and up 15% from $55 million in Q4 2025. Medincell receives mid‑ to high‑single‑digit royalties on UZEDY and may earn up to $105M in commercial milestones tied to annual sales thresholds. UZEDY is a 1‑ and 2‑month subcutaneous risperidone LAI approved in the U.S. for schizophrenia (Apr 2023) and Bipolar I Disorder (Oct 2025). Teva’s NDA for once‑monthly olanzapine LAI was accepted in Feb 2026; U.S. decision expected Q4 2026 and European MAA acceptance expected Q2 2026.
Teva (NYSE:TEVA) reported Q1 2026 revenue of $3,982 million, up 2% in U.S. dollars and down 3% in local currency. Key innovative brands grew strongly (AUSTEDO $578M, AJOVY $196M, UZEDY $63M) while generics declined; PONLIMSI received FDA approval and Teva agreed to acquire Emalex, expected to close by Q3 2026.
GAAP diluted EPS $0.31; non-GAAP diluted EPS $0.53; free cash flow $188 million; 2026 outlook maintained and updated for Emalex.
Teva (NYSE:TEVA) will acquire Emalex Biosciences for $700 million upfront, plus up to $200 million in commercial milestones and royalties on global net sales of ecopipam, subject to regulatory approval. Ecopipam is an NDA-ready, first-in-class selective D1 antagonist for pediatric Tourette syndrome with FDA Orphan Drug and Fast Track designations and positive Phase 3 primary endpoint results; NDA submission is anticipated in 2H 2026. The deal is expected to close by Q3 2026, funded from Teva cash on hand, and Teva said it will seek to mitigate near-term margin dilution while remaining on track for its 2027 targets.
Teva (NYSE: TEVA) launched Home Ground™ Schizophrenia Community on April 15, 2026, an online, no‑cost platform offering peer‑informed resources, symptom‑tracking tools, emotional‑wellness content, independent‑living guides, physical‑health prompts and event listings to support people living with schizophrenia and their care partners.
Content was developed with input from people living with schizophrenia, care partners and advocacy groups to reduce isolation and augment clinical care.
Teva (NYSE:TEVA), Direct Relief, and the National Association of Free and Charitable Clinics announced a second round of grants of $75,000 each to 11 free and charitable clinics in Alabama, Mississippi, and Texas on April 14, 2026. Teva previously committed an additional $2 million in 2024 after a 2022 launch.
In 2025 the grantee programs reached more than 57,000 people, completed nearly 6,000 depression and anxiety screenings, and trained over 260 providers. Funding supports expanded counseling, extended hours, telehealth, and outreach.
Teva (NYSE:TEVA) announced FDA approval of PONLIMSI (denosumab-adet) for all Prolia indications and acceptance of BLA/MAA filings for a proposed omalizumab biosimilar in the U.S. and EU. The EMA granted marketing authorization for PONLIMSI in November 2025, and FDA approval occurred on March 30, 2026.
Teva positions these regulatory milestones as part of its Pivot to Growth strategy to expand its global biosimilars portfolio and commercialization capabilities.
Teva (NYSE: TEVA) posted its Q1 2026 Aide Memoire to the Investors page to help investors ahead of first-quarter results. The document compiles previously disclosed public information, management commentary and select independent data.
Teva expects to release Q1 2026 results on April 29, 2026 at 7:00 AM ET, with a conference call at 8:00 AM ET.
Teva (NYSE: TEVA) will release its first quarter 2026 financial results on April 29, 2026 at 7:00 a.m. ET, followed by a conference call and live webcast at 8:00 a.m. ET the same day. Registration is required for phone participation and a replay will be available within 24 hours on Teva's investor website.
Teva (NYSE: TEVA) and Blackstone Life Sciences announced a $400 million strategic funding agreement over four years to support development of duvakitug, a human monoclonal antibody targeting TL1A in phase 3 studies for ulcerative colitis and Crohn’s disease.
BXLS may earn regulatory and commercial milestones plus low single-digit royalties on worldwide sales, and Teva remains co-developer/co-commercializer with Sanofi subject to regulatory approval.